RNA

Total RNA was prepared from cell line WM3268. WM3268 is a tumorigenic (VGP) primary melanoma cell line with competence for metastasis. These cells display mesenchymal morphology in culture. This cell line contains a Q61K mutation at position 61 in the N-RAS gene which causes increased signaling via the extracellular signal-regulated MAPK/ERK kinase pathways to enhance proliferation. WM3268 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3268. WM3268 is a tumorigenic (VGP) primary melanoma cell line with competence for metastasis. These cells display mesenchymal morphology in culture. This cell line contains a Q61K mutation at position 61 in the N-RAS gene which causes increased signaling via the extracellular signal-regulated MAPK/ERK kinase pathways to enhance proliferation. WM3268 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3282. WM3282 is a tumorigenic (VGP) primary melanoma cell line with competence for metastasis. These cells display pigmented, mesenchymal morphology in culture. This cell line contains V600K (Val600Lys) mutation at codon 600 in the BRAF gene. This mutation occurs within the activation segment of the kinase domain and causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. WM3282 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3282. WM3282 is a tumorigenic (VGP) primary melanoma cell line with competence for metastasis. These cells display pigmented, mesenchymal morphology in culture. This cell line contains V600K (Val600Lys) mutation at codon 600 in the BRAF gene. This mutation occurs within the activation segment of the kinase domain and causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. WM3282 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3282. WM3282 is a tumorigenic (VGP) primary melanoma cell line with competence for metastasis. These cells display pigmented, mesenchymal morphology in culture. This cell line contains V600K (Val600Lys) mutation at codon 600 in the BRAF gene. This mutation occurs within the activation segment of the kinase domain and causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. WM3282 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3301. WM3301 is a human metastatic melanoma cell line that displays flat cell morphology and requires insulin and 10% culture medium for growth. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses PTEN loss of function including homozygous deletion, and is wild type for N-RAS, c-KIT, and CDK4. WM3301 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3301. WM3301 is a human metastatic melanoma cell line that displays flat cell morphology and requires insulin and 10% culture medium for growth. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses PTEN loss of function including homozygous deletion, and is wild type for N-RAS, c-KIT, and CDK4. WM3301 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3301. WM3301 is a human metastatic melanoma cell line that displays flat cell morphology and requires insulin and 10% culture medium for growth. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses PTEN loss of function including homozygous deletion, and is wild type for N-RAS, c-KIT, and CDK4. WM3301 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3311. These cells are known to have mutations in GRIN2A, PRDM1, TERT, and are upregulated in Notch2. These cells are different from many melanoma cell lines in that they lack the common V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This cell line is wild type for BRAF, N-RAS, c-KIT, and CDK4. WM3311 cells produce xenograft tumors when injected into immunocompromised mice.